Study of glucagon response and its association with glycemic control and variability after administration of ipragliflozin as an adjunctive to insulin treatment in patients with type 1 diabetes (Suglat-AID): a single-arm, multicenter, open-label, prospective exploratory trial
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Suglat-AID
Most Recent Events
- 25 Apr 2024 Results assessing glucagon responses and its associations with glycaemic control and ketogenesis before and after T1D treatment with the sodium-glucose cotransporter 2 inhibitor, ipragliflozin published in the Diabetes, Obesity and Metabolism
- 02 Aug 2023 Status changed from recruiting to completed.
- 26 Jun 2023 Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association